Associated Papers
Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E et al.
Clinical Biochemistry, 2024
The Relevance of Noncoding DNA Variations of Paraoxonase Gene Cluster in Atherosclerosis-Related Diseases.
Wysocka A et al.
International Journal of Molecular Sciences, 2021
Genetic polymorphisms in amyotrophic lateral sclerosis: Evidence for implication in detoxification pathways of environmental toxicants.
Dardiotis E et al.
Environment International, 2018
Q192R polymorphism of paraoxonase 1 gene associated with insulin resistance in Mexican children.
Alegría-Torres JA et al.
Archives of Medical Research, 2015
Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease.
Belin AC et al.
Neuroscience Letters, 2012
Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases.
Androutsopoulos VP et al.
Toxicology and Applied Pharmacology, 2011
Frequency distribution of the single-nucleotide -108C/T polymorphism at the promoter region of the PON1 gene in Asian Indians and its relationship with coronary artery disease.
Ahmad I et al.
Journal of Community Genetics, 2011
Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis.
Riedmaier S et al.
Frontiers in Pharmacology, 2011
A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis.
Morahan JM et al.
Neurotoxicology, 2007
Polymorphisms in the human paraoxonase (PON1) promoter.
Brophy VH et al.
Pharmacogenetics, 2001
Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity.
Costa LG et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 0
Select a paper to view details